Celldex Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 26, 2024. Celldex is a clinical-stage biopharmaceutical company focused on therapeutic antibodies, particularly treatments targeting mast-cell-driven diseases. It had no product sales revenue.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $6.9 million | $2.4 million |
| Research and development expense | $118.0 million | $82.3 million |
| General and administrative expense | $30.9 million | $27.2 million |
| Operating loss | $154.5 million | $115.2 million |
| Investment and other income, net | $13.1 million | $2.9 million |
| Net loss | $141.4 million | $112.3 million |
| Basic and diluted loss per share | $2.92 | $2.40 |
| Net cash used in operating activities | $107.3 million | $103.7 million |
Revenue consisted primarily of contract manufacturing, research and development services, and grants; it is not product revenue. The filing does not provide a separate Q4 income statement summary. Cash, cash equivalents and marketable securities totaled $423.6 million at year-end, versus $305.0 million in 2022. Total liabilities were $36.5 million, including operating lease liabilities; the filing reports no material borrowings. Management estimates the year-end liquidity can fund current planned operations into 2026, while noting long-term funding needs and uncertainty around future financing.
Changes from the prior year
- Revenue rose $4.5 million, largely from increased services under manufacturing and R&D agreements with Rockefeller University.
- R&D expense increased 43% to $118.0 million, primarily reflecting expanded barzolvolimab clinical-trial and manufacturing activity. G&A rose 14%.
- Net loss widened by $29.1 million. Higher R&D costs and the absence of the prior-year $6.9 million contingent-consideration gain were partly offset by higher investment income and revenue.
- Investment income increased to $13.1 million, primarily due to higher interest rates and income from the sale of New Jersey tax benefits.
- The company raised $216.2 million net in a November 2023 public offering, issuing 8.54 million shares. Year-end shares outstanding increased to 55.88 million from 47.20 million.
Programs, outlook and key risks
- Barzolvolimab / CSU: The 208-patient Phase 2 study met its week-12 primary endpoint at all three dose regimens, with statistically significant improvement versus placebo; the company reported generally favorable tolerability. Two Phase 3 studies were planned to start in summer 2024, and 52-week data were expected in the second half of 2024.
- Other barzolvolimab indications: Phase 2 CIndU data were expected in the second half of 2024. A Phase 1b PN study showed signals of itch and lesion improvement; a Phase 2 study was planned for early 2024. The Phase 2 EoE study was enrolling, with the protocol amended to test 300 mg every four weeks.
- CDX-585: The bispecific antibody entered a Phase 1 dose-escalation study in advanced or metastatic solid tumors; enrollment was ongoing.
- Spending outlook: Management expects operating losses and significant R&D spending to continue, with operating cash use expected to increase as barzolvolimab development expands. It gave no product-sales or earnings guidance.
- Financing and dilution: An at-the-market agreement entered into in February 2024 permits sales of up to $300 million of common stock, at the company’s discretion. Future equity financing could dilute shareholders; debt or partnerships could impose costs or restrict economics.
- Settlement obligation: Celldex paid $12.5 million in 2023 after the CSU Phase 2 milestone was met. A further $52.5 million is payable upon the first FDA or EMA approval of a qualifying product; the company may pay in cash, shares, or a combination.
- Principal risks: Clinical efficacy and safety may not be confirmed in later trials; regulatory review, enrollment, manufacturing scale-up, reliance on CROs/CMOs, competition, reimbursement, intellectual-property protection and access to capital could delay or prevent commercialization. KIT inhibition has been associated with hair-color and taste changes, transient blood-count changes, and a nonclinical spermatogenesis finding that recovered in the reported animal follow-up.
The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting; management and the auditor concluded controls were effective as of December 31, 2023. The auditor identified R&D expense and CRO/CMO accrual estimates as a critical audit matter.
Investor verification priorities
- Review the full CSU Phase 2 results, including duration of benefit, dose selection, safety, and the forthcoming 52-week data; confirm whether the planned Phase 3 start occurred.
- Track CIndU, PN and EoE trial enrollment, data timing, and safety findings against management’s stated plans.
- Reassess cash runway using quarterly operating cash burn, development spending, and any actual ATM share sales; compare reported cash with the “into 2026” estimate.
- Monitor the $52.5 million approval-triggered SRS payment and its potential cash impact or shareholder dilution.
- Assess whether manufacturing scale-up and competitive positioning support the pathway from clinical results to regulatory approval and commercial access.